Iorhen E Akase1, Abdurazaq G Habib2, Adamu G Bakari3, Hamza Muhammad2, Ibrahim Gezawa4, Ibrahim Nashabaru2, Garba Iliyasu2, Abdullahi A Mohammed5. 1. Infectious Disease unit, Lagos University teaching Hospital, Lagos, Nigeria. 2. Infectious Disease unit, Bayero University; and Aminu Kano Teaching Hospital, Kano, Nigeria. 3. Endocrinology Unit, Ahmadu Bello University; and Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. 4. Endocrinology Unit, Bayero University; and Aminu Kano Teaching Hospital, Kano, Nigeria. 5. Infectious Disease unit, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
Abstract
BACKGROUND: The occurrence of endocrine diseases in people who are infected with HIV is traditionally thought to occur in the setting of AIDS with opportunistic infections and malignancies. However, recent studies find the correlation between hypocortisolism and stage of HIV (CD4 count and WHO clinical stage) inconsistent. METHODS: This descriptive cross-sectional study included three hundred and fifty (350) consecutive patients with HIV infection. They were interviewed, and subsequently underwent laboratory evaluation for the detection of hypocortisolism. Blood samples for serum cortisol estimation were taken at baseline and at 30 minutes following the administration of 1µg of tetracosactrin (Synacthen). In addition, the patients had blood samples taken at 0 minutes (baseline) for CD4+ lymphocyte cell counts. RESULTS: At baseline, 108 (30.9%) participants had serum cortisol levels below 100 µg/L with a median value of 55.48 µg/L (11.36-99.96 µg/L), but only 57 (16.3%) study participants had stimulated serum cortisol levels below 180 µg/L with median of 118 µg/L (19.43-179.62). There was no significant difference in the occurrence of clinical features between participants with low and normal serum cortisol, nor WHO clinical stage, CD4 count and ART regimen. The occurrence of hypocortisolism was higher among participants who had been on ART for a longer period of time. CONCLUSION: There is a high prevalence of hypocortisolism among HIV patients by biochemical testing, especially those who have been on ARVs for a longer duration. Hypocortisolism cannot be predicted based on the participants' WHO clinical stage of disease, CD4 cell count, or the treatment regimen. FUNDING: Personal Funds.
BACKGROUND: The occurrence of endocrine diseases in people who are infected with HIV is traditionally thought to occur in the setting of AIDS with opportunistic infections and malignancies. However, recent studies find the correlation between hypocortisolism and stage of HIV (CD4 count and WHO clinical stage) inconsistent. METHODS: This descriptive cross-sectional study included three hundred and fifty (350) consecutive patients with HIV infection. They were interviewed, and subsequently underwent laboratory evaluation for the detection of hypocortisolism. Blood samples for serum cortisol estimation were taken at baseline and at 30 minutes following the administration of 1µg of tetracosactrin (Synacthen). In addition, the patients had blood samples taken at 0 minutes (baseline) for CD4+ lymphocyte cell counts. RESULTS: At baseline, 108 (30.9%) participants had serum cortisol levels below 100 µg/L with a median value of 55.48 µg/L (11.36-99.96 µg/L), but only 57 (16.3%) study participants had stimulated serum cortisol levels below 180 µg/L with median of 118 µg/L (19.43-179.62). There was no significant difference in the occurrence of clinical features between participants with low and normal serum cortisol, nor WHO clinical stage, CD4 count and ART regimen. The occurrence of hypocortisolism was higher among participants who had been on ART for a longer period of time. CONCLUSION: There is a high prevalence of hypocortisolism among HIV patients by biochemical testing, especially those who have been on ARVs for a longer duration. Hypocortisolism cannot be predicted based on the participants' WHO clinical stage of disease, CD4 cell count, or the treatment regimen. FUNDING: Personal Funds.
Authors: Chukwuma O Ekpebegh; Anthonia O Ogbera; Benjamin Longo-Mbenza; Ernesto Blanco-Blanco; Ajani Awotedu; Patrick Oluboyo Journal: Med Princ Pract Date: 2011-10-04 Impact factor: 1.927
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Douglas S Kwon; Mathieu Angin; Tomoyuki Hongo; Kenneth M Law; Jessica Johnson; Filippos Porichis; Meghan G Hart; David F Pavlik; Daniel P Tighe; Daniel G Kavanagh; Hendrik Streeck; Marylyn M Addo; Daniel E Kaufmann Journal: J Virol Date: 2012-04-11 Impact factor: 5.103
Authors: David B Meya; Elly Katabira; Marcel Otim; Allan Ronald; Robert Colebunders; Denise Njama; Harriet Mayanja-Kizza; Christopher C Whalen; Merle Sande Journal: Afr Health Sci Date: 2007-06 Impact factor: 0.927